

**S3 Table.** Characteristics and outcomes of the patients receiving maintenance treatment

No.	Stage	Risk stratification	ALK status	CD30 status	Tumor site at diagnosis	Suspected residual tumor sites before maintenance <sup>a)</sup>	Maintenance treatment	Duration of maintenance treatment (yr)	Outcome
1	III	R2	+	+	Thorax	One mediastinal lymph node of 0.5×0.8 cm <sup>2</sup>	Crizotinib	1	No events
2	III	R2	+	+	Lymph node , maxillofacial region	A lesion of 0.6×0.7 cm <sup>2</sup> in the maxillofacial bone	Crizotinib	1	No events
3	III	R3	+	+	Multiple skin , bilateral pulmonary nodes , double kidneys	One node of 0.7×0.9 cm <sup>2</sup> in the right lung	Crizotinib	1	No events
4	III	R3	+	+	Lymph node, mediastinum , bilateral pulmonary nodes , right mandibular gland	One node of 0.3×0.5 cm <sup>2</sup> in the right lung	Crizotinib	1	No events
5	III	R2	+	+	Anterior superior mediastinum	One mediastinal lymph node of 0.4×0.6 cm <sup>2</sup>	Crizotinib	1	No events
6	III	R2	+	+	Lymph node, spleen	A lesion of 0.6×0.8 cm <sup>2</sup> in the spleen	Crizotinib	1	No events
7	III	R2	+	+	Lymph node	One retroperitoneal lymph node of 0.5×0.6 cm <sup>2</sup>	Crizotinib		No events
8	III	R3	+	+	Lymph node	One retroperitoneal lymph node of 0.4×0.6 cm <sup>2</sup>	Vinblastine	1	No events
9	III	R3	+	+	Lymph node, multiple skin, nasopharynx	A lesion of 0.6×0.7 cm <sup>2</sup> in the nasopharynx	Vinblastine	1	No events
10	III	R3	+	+	Maxillofacial region	A lesion of 0.5×0.8 cm <sup>2</sup> in the maxillofacial bone	Vinblastine	1	Relapse but survive after rescued

									treatment
11	III	R3	+	+	Middle and posterior mediastinum	One mediastinal lymph node of 0.3×0.5 cm <sup>2</sup>	Vinblastine	1	No events
12	III	R3	+	+	Lymph node , bilateral pulmonary , thoracic vertebra	A lesion of 0.4×0.6 cm <sup>2</sup> in the thoracic vertebra	Vinblastine	1	No events

ALK, anaplastic lymphoma kinase. <sup>a)</sup>Suspected positive residual tumors detected by positron emission tomography/computed tomography but not proved by pathology.